8-K: Gyre Therapeutics Announces Second Quarter 2024 Financial Results and Business Update

Gyre Therapeutics reported its second quarter 2024 financial results, highlighted by $25.2 million in revenue and progress in clinical development and commercial expansion.

Summary

• Gyre Therapeutics announced its financial results for the second quarter and first half of 2024, along with a business update.
• The company reported second-quarter revenue of $25.2 million, a decrease from $29.3 million in the same period of 2023, primarily due to normalized anti-fibrosis drug sales.
• Net income for the second quarter was $4.5 million, compared to $3.8 million in the same period last year.
• For the first six months of 2024, revenue was $52.4 million, down from $54.3 million in the first half of 2023.
• Net income for the first six months was $14.5 million, compared to $8.0 million in the same period last year.
• As of June 30, 2024, Gyre had $16.1 million in cash and cash equivalents, $9.0 million in short-term bank deposits, and $28.8 million in long-term certificates of deposit.
• The company expects its cash resources to fund operations for at least 12 months following the issuance of the financial statements.
• Gyre received NMPA approval for avatrombopag for CLD-associated thrombocytopenia and IND approval for F230 for pulmonary arterial hypertension.
• A U.S. IND submission for F351 in MASH-associated liver fibrosis is expected in late 2024, with Phase 3 trial data in CHB-associated liver fibrosis expected by early 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the regulatory approvals and clinical progress, but tempered by the decrease in revenue and increased operating expenses. The company is making progress but faces challenges.

Positives

• Gyre achieved a net income of $4.5 million for the second quarter of 2024, an increase compared to $3.8 million in the same period of 2023.
• The company has a strong cash position with $16.1 million in cash and cash equivalents, $9.0 million in short-term bank deposits, and $28.8 million in long-term certificates of deposit.
• Gyre received regulatory approvals for avatrombopag and F230, expanding its product pipeline.
• The acquisition of rights to nintedanib further strengthens Gyre's position in the pulmonary fibrosis market.
• The company is progressing its clinical development programs with key milestones expected in the near future.
• Gyre's inclusion in the Russell 2000 and 3000 Indexes is a positive recognition of its market position.

Negatives

• Second-quarter revenue decreased to $25.2 million from $29.3 million in the same period of 2023, primarily due to a decrease in sales volume of ETUARY.
• The company experienced a $4.1 million decrease in revenue for the quarter, with $3.9 million attributed to decreased sales volume and $0.2 million due to foreign currency exchange rate impacts.
• Selling and marketing expenses remain high at $14.4 million for the quarter, although this is a decrease from $18.0 million in the same period of 2023.
• General and administrative expenses increased to $3.4 million for the quarter, compared to $1.7 million in the same period of 2023, due to costs associated with being a public company.

Risks

• The company's future success depends on the outcome of clinical trials and regulatory approvals.
• There is a risk that clinical trial results may not be positive or predictive of future results.
• Competition from other pharmaceutical companies could impact Gyre's market share.
• The company's financial performance is subject to general economic, health, industrial, and political conditions.
• Gyre's ability to raise additional capital is a risk factor that could impact its operations.
• The company's revenue is subject to fluctuations in foreign currency exchange rates.

Future Outlook

Gyre anticipates that its cash resources as of June 30, 2024 will enable it to fund operations through at least 12 months following the issuance of the condensed consolidated financial statements. The company expects to report data from its Phase 3 trial of F351 in CHB-associated liver fibrosis in the PRC by early 2025, and pending these results and approval of its IND application, plans to initiate a U.S. Phase 2a trial of F351 in MASH-associated liver fibrosis in 2025.

Management Comments

• Han Ying, Ph.D., Chief Executive Officer of Gyre Therapeutics, stated that they are extremely proud of their advancements expanding commercial product offerings and therapeutic reach in the PRC.
• Management highlighted the NMPA approval for avatrombopag in CLD-associated thrombocytopenia and the IND approval for F230 in PAH as key achievements.

Industry Context

This announcement reflects Gyre's continued efforts to expand its commercial presence and clinical pipeline in the biotechnology sector, particularly in the areas of liver and pulmonary diseases. The company's focus on both commercial-stage products and clinical development programs positions it to compete in the market for treatments for chronic organ diseases. The acquisition of rights to nintedanib and the regulatory approvals for avatrombopag and F230 are significant steps in this direction.

Comparison to Industry Standards

• Gyre's revenue of $25.2 million for the quarter is comparable to other commercial-stage biotech companies of similar size, although the decrease from the previous year highlights the impact of normalized sales after a COVID-related surge.
• The company's cash position of $16.1 million, combined with short-term deposits and long-term certificates of deposit, is relatively strong compared to other companies in the sector, providing a runway for ongoing operations and clinical trials.
• The regulatory approvals for avatrombopag and F230 are significant achievements, placing Gyre in a competitive position with companies like Gilead Sciences and Intercept Pharmaceuticals, which also focus on liver disease treatments.
• The planned Phase 2a trial of F351 in MASH-associated liver fibrosis in the U.S. is a key milestone, aligning with the industry's focus on developing treatments for this growing disease area, similar to efforts by companies like Madrigal Pharmaceuticals and Viking Therapeutics.
• The expected topline data from the Phase 3 trial of F351 in CHB-associated liver fibrosis in the PRC is a critical event, comparable to other companies' late-stage clinical trial readouts, such as those by Assembly Biosciences and Arbutus Biopharma.

Management Changes

Stakeholder Impact

• Shareholders may be impacted by the decrease in revenue and increased operating expenses, but also by the positive clinical and regulatory developments.
• Employees may be impacted by changes in staffing and operational costs.
• Patients may benefit from the development of new treatments for liver and pulmonary diseases.
• Suppliers and creditors may be impacted by the company's financial performance and cash position.

Next Steps

• Gyre plans to submit a U.S. IND application for F351 in MASH-associated liver fibrosis by the end of 2024.
• The company expects to report topline data from its Phase 3 trial of F351 in CHB-associated liver fibrosis in the PRC by early 2025.
• Gyre intends to initiate a Phase 2a clinical trial of F351 in MASH-associated liver fibrosis in 2025.
• The company plans to initiate a Phase 1 trial of F230 in PAH in 2025.

Key Dates

Keywords

Gyre Therapeutics, Financial Results, Avatrombopag, Nintedanib, F351, F230, MASH, Liver Fibrosis, Pulmonary Arterial Hypertension, Clinical Trials, Pharmaceuticals, Biotechnology